光动力治疗药物光敏剂的治疗学特点及临床评价要素  

Therapeutic characteristics and clinical evaluation element of the photosensitive drugs

作　　者：谢松梅[1] 符世平[2] 

机构地区：[1]国家食品药品监督管理局药品审评中心,北京100038 [2]洛阳市中心医院,洛阳471009

出　　处：《中国新药杂志》2008年第7期618-620,624,共4页Chinese Journal of New Drugs

摘　　要：目前,光敏剂辅助的光动力疗法已在恶性肿瘤和某些皮肤病、老年性视网膜黄斑病、局部细菌感染等良性疾病的治疗中发挥了重要作用,新一代光敏剂的研发已成为人们关注的热点。现结合有关光敏剂和光动力治疗的治疗学特点、当前国内光敏剂申报中存在的问题等,探讨光敏药物研发关键点,以期为国内该类药物安全有效性的综合评价提供参考。Recently, PDT following application of photosensitive drugs has played an important role in malignant tumors and some innocuousness disease such as some skin diseases, senile macular degeneration and topical bacterial infection. Therefore, the investigators pay more attention to the development of new photosensitive drugs. Based on the therapeutic characteristics of these drugs and the questions in new photosensitive drug application in China, in this review we indicated the key points of safety and effectiveness evaluation in the development of the photosensitive drugs.

关 键 词：光敏剂 光动力治疗 临床评价 

分 类 号：R914[医药卫生—药物化学]